News

Medical Dialogues10h
Once-Monthly MariTide Shows Promising Weight Loss in Obesity and Type 2 Diabetes: Phase 2 Trial
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...
Zacks.com on MSN2h
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
New Atlas1d
A once-monthly jab cuts body weight by 16% in groundbreaking obesity trial
A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...
TCTMD1d
Weight-Loss Drug MariTide Gains Momentum in Phase II Trial
The once-monthly drug is still under study but could provide added convenience and another option for patients.
Applied Clinical Trials Online3d
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...
STAT3d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
BioPharma Dive3d
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...